{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:55:31Z","timestamp":1766141731081,"version":"3.48.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020365","name":"Centers for Disease Control and Prevention Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Hydroxyurea reduces severe disease among individuals living with sickle cell disease (SCD). These individuals experience high acute care utilization, but the associations between patterns of hydroxyurea utilization and healthcare utilization are not well investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to determine the association between hydroxyurea use and healthcare utilization among individuals with SCD in Tennessee (TN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We conducted a population-based, retrospective cohort study of individuals with SCD using secondary data analysis of Tennessee Medicaid, Medicare, and BlueCross BlueShield of Tennessee (BCBS-TN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 4,901 individuals with SCD were included in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Hydroxyurea adherence was estimated using the medication possession ratio (MPR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and measures<\/jats:title>\n                    <jats:p>The incidence rate ratios of hospitalizations, emergency department visits, and mortality were calculated using negative-binomial models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The prevalence of hydroxyurea prescription dispensation for the state was low (21% for TennCare, 21% for Medicare, and 17% for BCBS-TN). In TennCare and BCBS-TN, those younger than 18 had more hydroxyurea utilization, and individuals with HbSS or HbS\u03b2\n                      <jats:sup>0<\/jats:sup>\n                      thalassemia filled more hydroxyurea than those with other subtypes (30.5% in TennCare and 23.4% in BCBS-TN). The MPR for the entire state was 19.7%. There was a dose\u2013response relationship between hydroxyurea adherence and the incidence of acute healthcare utilization, except in 18\u201325-year-olds. We also found lower mortality in those with higher hydroxyurea adherence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and relevance<\/jats:title>\n                    <jats:p>In our pooled statewide analysis, hydroxyurea MPR was low. Higher hydroxyurea use was associated with decreased acute healthcare utilization and lower mortality. Interventions to support patient adherence and provider prescribing are required to improve health outcomes among individuals with SCD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1693126","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:49:56Z","timestamp":1766141396000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hydroxyurea utilization among individuals with sickle cell disease in Tennessee: a pooled analysis of claims data"],"prefix":"10.3389","volume":"16","author":[{"given":"Ayesha","family":"Mukhopadhyay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew P.","family":"Smeltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif M.","family":"Badawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joacy G.","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison P.","family":"Plaxco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith A.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Wiese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter I.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Gurney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinonyelum","family":"Nwosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerlym S.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Klesges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane S.","family":"Hankins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William O.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12288-013-0261-4","article-title":"Hydroxyurea in sickle cell disease: drug review","volume":"30","author":"Agrawal","year":"2014","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e14884","DOI":"10.2196\/14884","article-title":"Development of the InCharge health Mobile app to improve adherence to hydroxyurea in patients with sickle cell disease: user-centered design approach","volume":"8","author":"Alberts","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1182\/blood.v97.11.3628","article-title":"Five years of experience with hydroxyurea in children and young adults with sickle cell disease","volume":"97","author":"Alina","year":"2001","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD011175","DOI":"10.1002\/14651858.CD011175.pub2","article-title":"Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications","volume":"10","author":"Asnani","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/pbc.25905","article-title":"Technology access and smartphone app preferences for medication adherence in adolescents and young adults with sickle cell disease","volume":"63","author":"Badawy","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/ejh.12878","article-title":"Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease","volume":"98","author":"Badawy","year":"","journal-title":"Eur. J. Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12955-017-0713-x","article-title":"Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults","volume":"15","author":"Badawy","year":"","journal-title":"Health Qual. Life Outcomes"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e26369","DOI":"10.1002\/pbc.26369","article-title":"Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease","volume":"64","author":"Badawy","year":"","journal-title":"Pediatr. Blood Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8296139","DOI":"10.1155\/2018\/8296139","article-title":"Association between participants' characteristics, patient-reported outcomes, and clinical outcomes in youth with sickle cell disease","volume":"2018","author":"Badawy","year":"","journal-title":"Biomed. Res. Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/08880018.2018.1505988","article-title":"Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease","volume":"35","author":"Badawy","year":"","journal-title":"Pediatr. Hematol. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.hemonc.2018.01.001","article-title":"Beliefs about hydroxyurea in youth with sickle cell disease","volume":"11","author":"Badawy","year":"","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1477-7525-4-59","article-title":"Hydroxyurea and sickle cell anemia: effect on quality of life","volume":"4","author":"Ballas","year":"2006","journal-title":"Health Qual. Life Outcomes"},{"key":"B13","doi-asserted-by":"publisher","first-page":"E345","DOI":"10.1002\/ajh.25233","article-title":"Opioid utilization patterns in United States individuals with sickle cell disease","volume":"93","author":"Ballas","year":"2018","journal-title":"Am. J. Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ajh.25421","article-title":"Heritability of fetal hemoglobin, white cell count, and other clinical traits from a sickle cell disease family cohort","volume":"94","author":"Bao","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e20183285","DOI":"10.1542\/peds.2018-3285","article-title":"Hydroxyurea use for sickle cell disease among medicaid-enrolled children","volume":"144","author":"Brousseau","year":"2019","journal-title":"Pediatrics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/ajh.21968","article-title":"Hydroxyurea adherence and associated outcomes among medicaid enrollees with sickle cell disease","volume":"86","author":"Candrilli","year":"2011","journal-title":"Am. J. Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13104-015-1344-0","article-title":"Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision","volume":"8","author":"Creary","year":"2015","journal-title":"BMC Res. Notes"},{"key":"B19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3122\/jabfm.2020.01.190143","article-title":"Sickle-cell disease co-management, health care utilization, and hydroxyurea use","volume":"33","author":"Crego","year":"2020","journal-title":"J. Am. Board Fam. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/adc.2009.175125","article-title":"A systematic review of interventions to enhance medication adherence in children and adolescents with chronic illness","volume":"95","author":"Dean","year":"2010","journal-title":"Arch. Dis. Child."},{"key":"B21","unstructured":"About us\n          \n          \n          2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1590\/0034-7167-2016-0409","article-title":"Quality of life in adults with sickle cell disease: an integrative review of the literature","volume":"71","author":"Freitas","year":"2018","journal-title":"Rev. Bras. Enferm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1097\/MD.0000000000000215","article-title":"From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia","volume":"93","author":"Hankins","year":"2014","journal-title":"Med. Baltim."},{"key":"B24","doi-asserted-by":"publisher","first-page":"7190","DOI":"10.1182\/bloodadvances.2023010670","article-title":"A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease","volume":"7","author":"Hankins","year":"2023","journal-title":"Blood Adv."},{"key":"B25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00277-021-04450-x","article-title":"Alpha thalassemia, but not \u03b2(S)-globin haplotypes, influence sickle cell anemia clinical outcome in a large, single-center Brazilian cohort","volume":"100","author":"Hatzlhofer","year":"2021","journal-title":"Ann. Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e27650","DOI":"10.2196\/27650","article-title":"Engaging caregivers and providers of children with sickle cell anemia in shared decision making for hydroxyurea: protocol for a multicenter randomized controlled trial","volume":"10","author":"Hood","year":"2021","journal-title":"JMIR Res. Protoc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1177\/1357633x19883558","article-title":"A feasibility study of telemedicine for paediatric sickle cell patients living in a rural medically underserved area","volume":"27","author":"Jacob","year":"2021","journal-title":"J. Telemed. Telecare"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.18553\/jmcp.2020.26.11.1412","article-title":"The association between hydroxyurea adherence and opioid utilization among Texas medicaid enrollees with sickle cell disease","volume":"26","author":"Kang","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1182\/bloodadvances.2020001743","article-title":"Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects","volume":"4","author":"Kanter","year":"2020","journal-title":"Blood Adv."},{"key":"B30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/0033354919881438","article-title":"Reducing health care disparities in sickle cell disease: a review","volume":"134","author":"Lee","year":"2019","journal-title":"Public Health Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/jpepsy\/jsv084","article-title":"Systematic and meta-analytic review: medication adherence among pediatric patients with sickle cell disease","volume":"41","author":"Loiselle","year":"2016","journal-title":"J. Pediatr. Psychol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1915374","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"B33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/2150131916662969","article-title":"Attitudes of primary care physicians toward sickle cell disease care, guidelines, and comanaging hydroxyurea with a specialist","volume":"8","author":"Lunyera","year":"2017","journal-title":"J. Prim. Care Community Health"},{"key":"B34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/jha2.7","article-title":"A meta-analysis of toxicities related to hydroxycarbamide dosing strategies","volume":"1","author":"Mathias","year":"2020","journal-title":"eJHaem"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1097\/ajp.0000000000000361","article-title":"Multiple levels of suffering: discrimination in health-care settings is associated with enhanced laboratory pain sensitivity in sickle cell disease","volume":"32","author":"Mathur","year":"2016","journal-title":"Clin. J. Pain"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1111\/jan.12760","article-title":"Perceptions of young adults with sickle cell disease concerning their disease experience","volume":"72","author":"Matthie","year":"2016","journal-title":"J. Adv. Nurs."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e29685","DOI":"10.1002\/pbc.29685","article-title":"Healthcare utilization and the quality of life of children and adolescents with sickle cell disease","volume":"69","author":"Moody","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"B38","unstructured":"Blood institute evidence-based management of sickle cell disease: expert panel report\n          \n          \n            \n              National Heart\n              L.\n            \n          \n          \n          2014"},{"key":"B39","first-page":"S335","article-title":"Sickle cell disease: current treatment and emerging therapies","volume":"25","author":"Neumayr","year":"2019","journal-title":"Am. J. Manag. Care"},{"key":"B40","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1108\/IJHCQA-01-2013-0008","article-title":"Differences in quality of life between pediatric sickle cell patients who used hydroxyurea and those who did not","volume":"27","author":"Nwenyi","year":"2014","journal-title":"Int. J. Health Care Qual. Assur"},{"key":"B41","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/bjh.19099","article-title":"Provider prescription of hydroxyurea in youth and adults with sickle cell disease: a review of prescription barriers and facilitators","volume":"203","author":"Pizzo","year":"2023","journal-title":"Br. J. Haematol."},{"key":"B42","unstructured":"Sickle cell data collection (SCDC) program\n          \n          \n          2023"},{"key":"B43","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1186\/s12913-019-4726-5","article-title":"Not being heard: barriers to high quality unplanned hospital care during young people's transition to adult services - evidence from 'this sickle cell life' research","volume":"19","author":"Renedo","year":"2019","journal-title":"BMC Health Serv. Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12955-019-1225-7","article-title":"Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study","volume":"17","author":"Shah","year":"2019","journal-title":"Health Qual. Life Outcomes"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1080\/13696998.2020.1813144","article-title":"Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, medicaid, and medicare insurance - the perspective of private and public payers","volume":"23","author":"Shah","year":"2020","journal-title":"J. Med. Econ."},{"key":"B46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jpeds.2018.01.054","article-title":"HABIT, a randomized feasibility trial to increase hydroxyurea adherence, suggests improved health-related quality of life in youths with sickle cell disease","volume":"197","author":"Smaldone","year":"2018","journal-title":"J. Pediatr."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e050880","DOI":"10.1136\/bmjopen-2021-050880","article-title":"Identifying barriers to evidence-based care for sickle cell disease: results from the sickle cell disease implementation consortium cross-sectional survey of healthcare providers in the USA","volume":"11","author":"Smeltzer","year":"2021","journal-title":"BMJ Open"},{"key":"B48","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ajh.22016","article-title":"Transition from pediatric to adult care for sickle cell disease: results of a survey of pediatric providers","volume":"86","author":"Sobota","year":"2011","journal-title":"Am. J. Hematol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am. J. Hematol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"100982","DOI":"10.1016\/j.blre.2022.100982","article-title":"Health related quality of life in children with sickle cell disease: a systematic review and meta-analysis","volume":"56","author":"Stokoe","year":"2022","journal-title":"Blood Rev."},{"key":"B51","unstructured":"TN.gov TSG-. This is TennCare\n          \n          \n          2025"},{"key":"B52","unstructured":"About us\n          \n          \n          2025"},{"key":"B53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000500258","article-title":"Pediatric to adult transition in sickle cell Disease: survey results from young adult patients","volume":"143","author":"Travis","year":"2020","journal-title":"Acta Haematol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1813598","article-title":"Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa","volume":"380","author":"Tshilolo","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1188\/20.CJON.451-454","article-title":"Young adults with sickle cell disease: challenges with transition to adult health care","volume":"24","author":"Varty","year":"2020","journal-title":"Clin. J. Oncol. Nurs."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e27778","DOI":"10.1002\/pbc.27778","article-title":"Hydroxyurea for children with sickle cell anemia: prescribe it early and often","volume":"66","author":"Ware","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1182\/blood-2014-08-435768","article-title":"Update on the use of hydroxyurea therapy in sickle cell disease","volume":"124","author":"Wong","year":"2014","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2122056","DOI":"10.1155\/2022\/2122056","article-title":"Health-related quality of life and adherence to hydroxyurea and other disease-modifying therapies among individuals with sickle cell disease: a systematic review","volume":"2022","author":"Yang","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1693126\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:49:58Z","timestamp":1766141398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1693126\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":61,"alternative-id":["10.3389\/fphar.2025.1693126"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1693126","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"article-number":"1693126"}}